Literature DB >> 27319291

FDA drug labeling: rich resources to facilitate precision medicine, drug safety, and regulatory science.

Hong Fang1, Stephen C Harris1, Zhichao Liu1, Guangxu Zhou1, Guoping Zhang1, Joshua Xu1, Lilliam Rosario2, Paul C Howard1, Weida Tong3.   

Abstract

Here, we provide a concise overview of US Food and Drug Administration (FDA) drug labeling, which details drug products, drug-drug interactions, adverse drug reactions (ADRs), and more. Labeling data have been collected over several decades by the FDA and are an important resource for regulatory research and decision making. However, navigating through this data is challenging. To aid such navigation, the FDALabel database was developed, which contains a set of approximately 80000 labeling data. The full-text searching capability of FDALabel and querying based on any combination of specific sections, document types, market categories, market date, and other labeling information makes it a powerful and attractive tool for a variety of applications. Here, we illustrate the utility of FDALabel using case scenarios in pharmacogenomics biomarkers and ADR studies. Published by Elsevier Ltd.

Mesh:

Year:  2016        PMID: 27319291     DOI: 10.1016/j.drudis.2016.06.006

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  4 in total

Review 1.  Enabling Technologies for Personalized and Precision Medicine.

Authors:  Dean Ho; Stephen R Quake; Edward R B McCabe; Wee Joo Chng; Edward K Chow; Xianting Ding; Bruce D Gelb; Geoffrey S Ginsburg; Jason Hassenstab; Chih-Ming Ho; William C Mobley; Garry P Nolan; Steven T Rosen; Patrick Tan; Yun Yen; Ali Zarrinpar
Journal:  Trends Biotechnol       Date:  2020-01-21       Impact factor: 19.536

2.  Information Extraction From FDA Drug Labeling to Enhance Product-Specific Guidance Assessment Using Natural Language Processing.

Authors:  Yiwen Shi; Ping Ren; Yi Zhang; Xiajing Gong; Meng Hu; Hualou Liang
Journal:  Front Res Metr Anal       Date:  2021-06-10

Review 3.  Drug-Induced Rhabdomyolysis Atlas (DIRA) for idiosyncratic adverse drug reaction management.

Authors:  Zhining Wen; Yu Liang; Yingyi Hao; Brian Delavan; Ruili Huang; Mike Mikailov; Weida Tong; Menglong Li; Zhichao Liu
Journal:  Drug Discov Today       Date:  2018-06-11       Impact factor: 7.851

4.  International Coherence of Pediatric Drug Labeling for Drug Safety: Comparison of Approved Labels in Korea and the United States.

Authors:  Yun-Kyoung Song; Nayoung Han; Gilbert J Burckart; Jung Mi Oh
Journal:  Clin Pharmacol Ther       Date:  2019-11-10       Impact factor: 6.875

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.